HSBC TUR.WAR.OP.END. 22UA/ DE000HS5L0P1 /
11/04/2024 17:35:10 | Chg.- | Bid17:49:47 | Ask17:49:47 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.1400EUR | - | - Bid Size: 25,000 |
- Ask Size: 25,000 |
BIONTECH SE SPON. AD... | 87.0466 - | 31/12/2078 | Call |
GlobeNewswire
17/05
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
GlobeNewswire
22/04
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
GlobeNewswire
07/04
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...
GlobeNewswire
20/03
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire
20/03
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
GlobeNewswire
11/03
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidat...
GlobeNewswire
06/03
BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update ...
GlobeNewswire
08/02
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire
31/01
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjuga...
GlobeNewswire
22/01
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/...
GlobeNewswire
09/01
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
21/12/2023
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Can...
GlobeNewswire
18/12/2023
BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
GlobeNewswire
06/11/2023
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
GlobeNewswire
26/10/2023
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Agains...
GlobeNewswire
23/10/2023
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advance...